Abhraka Bhasma: Benefits, Evidence & Safety

TL;DR

Abhraka Bhasma is calcined biotite mica, used in Ayurveda as a rasayana, including for respiratory complaints. Animal studies only: diabetic rats had lower blood glucose and lipids; mice showed no genotoxicity. A 28-day rat study found therapeutic doses safe, but higher doses caused reversible liver injury. No human trials exist. Use only under qualified supervision.

What it is

Abhraka is the Ayurvedic name for mica, classically biotite mica, a layered silicate mineral containing iron, magnesium, potassium, calcium, and aluminum. Abhraka has a monograph among the mineral raw materials standardized in the Ayurvedic Pharmacopoeia of India, Part I, Volume VII (minerals and metals) (Tier 1: API Pt. I Vol. VII, monograph 1, contents listing).

Abhraka Bhasma is produced by shodhana (purification, e.g. repeated heating and quenching in herbal liquids) followed by marana (calcination) through many puta cycles. Preparations named shataputi (100 cycles) or sahasraputi (1,000 cycles) denote the extent of processing, with more cycles traditionally reserved for rasayana (rejuvenative) use (conceptual review of Abhraka).

Like other classical bhasmas, the finished product is a very fine ash. Peer-reviewed analysis of traditional bhasmas including Abhrak bhasma, using X-ray diffraction, transmission electron microscopy, and particle-size measurement, found nanometer-scale dimensions (Journal of Biomedical Nanotechnology review). One characterization of Abhraka Bhasma reported two particle-size populations peaking around 63–200 nm (micro-filtered) and 103–487 nm (unfiltered) (Manipal genotoxicity study).

Nanometer-scale is a measurement, not a safety claim. I say that because "nano" gets used both to impress and to frighten, and neither is what the paper shows.

Traditional use

Rasa Shastra texts describe Abhraka as therapeutically useful across several systems: respiratory disorders (Kasa, cough; Shwasa, dyspnea/asthma), nervous-system conditions, digestive disorders, Pandu (anemia), and liver disorders, and regard extensively processed (sahasraputi) Abhraka as a rasayana for wasting and chronic debility (conceptual review of Abhraka, citing Rasa texts). Classical sources also describe it as tridosha-pacifying.

These are traditional claims, not clinical proof. The modern evidence is assessed separately below, and the gap between the two is wider here than for any other article in this batch. I want you to feel that gap.

What modern research says

Antihyperglycemic effects in diabetic rats

In streptozotocin-induced diabetic rats, Abhrak Bhasma treatment produced a significant decrease in blood glucose, total cholesterol, and triglyceride levels, with the authors concluding the preparation was safe and nontoxic in rats at the tested doses and showed beneficial metabolic effects (animal study, single trial) (Gopinath & Shivashankar, J. Ayurveda & Integrative Medicine, 2021).

This is animal evidence. It does not establish any antidiabetic effect in people. One trial, in rats, is the beginning of a research program, not the end of one.

Genotoxicity and DNA repair in mice

In Swiss albino mice, Abhraka Bhasma at 120 and 360 mg/kg for 7 days showed no genotoxic or reproductive toxicity (sperm count and abnormalities unchanged vs control). The higher dose additionally showed a protective effect against ethyl methanesulfonate–induced chromosomal damage and enhanced constitutive DNA base-excision repair (animal study) (Manipal University study, J. Ayurveda & Integrative Medicine). Interesting laboratory findings. Not evidence of benefit in humans. The distance between "protected mouse chromosomes from a mutagen" and "good for you" is enormous, and I will not help anyone jump it.

Acute and subacute toxicity in rats

A 2024 toxicity study of standardized Krishna Vajra Abhraka Bhasma in Wistar rats found no mortality or behavioral changes at a single 2000 mg/kg limit dose (placing it in GHS Category V), and no significant changes in body/organ weights, hematology, or renal function at therapeutic doses over 28 days. But mid and high doses produced reversible, dose-dependent hepatotoxicity on biochemical and histopathological evaluation (J. Ayurveda & Integrative Medicine, 2024). The authors emphasize careful dosage and patient monitoring in Ayurvedic practice.

Read that paragraph twice, because it is the core of this article. Safe at therapeutic doses in rats for 28 days. Liver injury at higher doses. Reversible, dose-dependent, and real.

What the evidence does not support (yet)

No human randomized controlled trials of Abhraka Bhasma were found. Its traditional uses (respiratory support, rejuvenation, metabolic effects) have not been tested for efficacy or safety in people. The evidence base is limited to classical texts and small animal studies. Everything beyond that is running ahead of the data, and on this preparation I treat that as a safety issue, not just an accuracy issue.

Safety & contraindications

The dose makes the poison with Abhraka Bhasma. The 2024 rat toxicity study is the most directly relevant safety evidence: therapeutic-level doses were non-toxic over 28 days, but mid and high doses caused reversible, dose-dependent liver injury. That is why the study's authors stress careful dosage and patient monitoring (JAIM, 2024). Rat data cannot be extrapolated to humans. But the finding means unsupervised dose escalation is specifically unwise with this preparation. I will not soften that.

Broader category risks apply. A peer-reviewed survey of 43 Ayurvedic formulations found 73.8% contained mercury, arsenic, or lead above FAO/WHO permissible limits (Ayush limits: lead 10, arsenic 3, cadmium 0.3, mercury 1 µg/g) (PMC survey), and NCCIH warns that some Ayurvedic preparations may contain lead, mercury, or arsenic in amounts that can be toxic (NCCIH's Ayurvedic Medicine: In Depth page). India's Department of Ayush mandates heavy-metal testing for exported Ayurvedic medicines (PIB release).

Do not self-administer Abhraka Bhasma. Use it only under a qualified practitioner (ideally with liver-function awareness given the animal hepatotoxicity signal), only from a GMP-certified manufacturer, and never in pregnancy, breastfeeding, or childhood unless a qualified practitioner specifically advises it. Non-standard or improperly incinerated preparations may contain untransformed mineral and pose real toxicity risks. Every clause of that paragraph is load-bearing.

FAQs

What is Abhraka Bhasma made from?

Abhraka Bhasma is made from Abhraka: mica, classically biotite mica, a layered silicate mineral containing iron, magnesium, potassium, calcium, and aluminum. It is purified (shodhana) and then calcined (marana) through many high-heat puta cycles (100 for shataputi, 1,000 for sahasraputi) into a very fine ash with nanometer-scale particles (conceptual review of Abhraka; J. Biomedical Nanotechnology review).

What does modern research say about Abhraka Bhasma?

Three small animal studies exist, and I will summarize all three because there is nothing else. Abhrak Bhasma lowered blood glucose, cholesterol, and triglycerides in diabetic rats; it showed no genotoxic or reproductive toxicity in mice and appeared to protect against chemically induced chromosomal damage. And a 28-day rat toxicity study found therapeutic doses safe but higher doses reversibly hepatotoxic (JAIM, 2021; Manipal study; JAIM, 2024). No human trials exist, so none of this establishes effects in people. That is the complete human-relevant summary: there isn't one.

Can Abhraka Bhasma damage the liver?

In rats, yes at higher doses. A 2024 study found reversible, dose-dependent hepatotoxicity at mid and high doses over 28 days, while therapeutic-level doses were non-toxic (JAIM, 2024). Whether this translates to humans is unknown, but it is the reason the researchers call for careful dosing and monitoring. Anyone with liver disease should not take it without specialist medical guidance. I would extend that: anyone at all should not take it without qualified supervision.

Is Abhraka Bhasma safe?

Human safety data do not exist. That sentence should end most conversations about taking it. In rats, an acute limit dose of 2000 mg/kg caused no deaths (GHS Category V), and 28-day therapeutic dosing was non-toxic. Higher doses injured the liver reversibly (JAIM, 2024). Separately, contamination surveys show toxic metals above permissible limits are common in Ayurvedic products generally (PMC). Safety data is limited. Talk to a clinician, and never self-dose.

What do "shataputi" and "sahasraputi" mean?

They denote the number of puta (calcination) cycles the mica underwent: 100 for shataputi, 1,000 for sahasraputi. Classical texts associate more cycles with finer particles and greater potency, reserving sahasraputi preparations for rasayana (rejuvenative) use (conceptual review of Abhraka). This is a traditional quality concept, not a clinically validated dose–response relationship. Do not read "1,000 cycles" as "proven 10x better."

Why is there no dosage section in this article?

Our editorial rule is to state doses only with a pharmacopoeial monograph or clinical-trial citation. No human trial of Abhraka Bhasma establishes a dose, and the rat toxicity study specifically shows harm at higher doses. So we omit one rather than repeat unverified figures. A qualified practitioner individualizes dose and duration, with monitoring. Omitting the dose is the safety decision. I stand by it.

Sources

The most safety-relevant paper is the 2024 toxicity study of standardized Krishna Vajra Abhraka bhasma, published in the Journal of Ayurveda & Integrative Medicine: acute limit dose 2000 mg/kg, GHS Category V; 28-day subacute study with therapeutic doses non-toxic and mid/high doses reversibly hepatotoxic (full text). The metabolic findings in diabetic rats are Gopinath and Shivashankar's 2021 study in the same journal (PDF), which reported reduced blood glucose, cholesterol, and triglycerides with no significant toxicity at the tested doses.

The genotoxicity and DNA-repair findings are from the Manipal University mouse study, also in the Journal of Ayurveda & Integrative Medicine (record): not genotoxic, no reproductive toxicity, protective against EMS-induced chromosomal damage. Preparation details and traditional indications come from the conceptual review of Abhraka in the International Journal of Pharma & Pharmaceutical Research (PDF), and the nanometer-scale characterization of classical bhasmas from the Journal of Biomedical Nanotechnology review (Ingenta).

The heavy-metal context is the PMC survey finding 73.8% of 43 sampled formulations above permissible limits for mercury, arsenic, or lead (PMC8882783); NCCIH's warning on toxic metals in some Ayurvedic preparations (NCCIH's Ayurvedic Medicine: In Depth page); and the Government of India's PIB release on mandatory heavy-metal testing and labeling (PIB).

Disclaimer

This article is for educational purposes only and is not medical advice. Abhraka Bhasma is a herbo-mineral preparation with a documented liver-injury signal at higher doses in animals and no human safety data. Do not self-administer it. Talk to a qualified healthcare practitioner before use, especially if you are pregnant, breastfeeding, managing liver disease or any medical condition, or taking prescription medicines.